<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Castle Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/castle-biosciences-inc</link>
<description>Latest news and press releases for Castle Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/castle-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355a3178dffbe2df0eb60a.webp</url>
<title>Castle Biosciences Inc</title>
<link>https://6ix.com/company/castle-biosciences-inc</link>
</image>
<item>
<title>Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-to-present-new-data-demonstrating-decisiondxr-melanomas-ability-to-identify-patients-with-greater-risk-of-recurrence-and-poor-outcomes-within-early-stage-melanoma-at-eado-and-acms</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-to-present-new-data-demonstrating-decisiondxr-melanomas-ability-to-identify-patients-with-greater-risk-of-recurrence-and-poor-outcomes-within-early-stage-melanoma-at-eado-and-acms</guid>
<pubDate>Tue, 21 Apr 2026 11:00:00 GMT</pubDate>
<description>Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it will present new data on its DecisionDx-Melanoma test addressing a critical clinical challenge in melanoma care: identifying which patients with early-stage disease are at risk for poor outcomes and may benefit from intensified management. The data will be presented at the 22nd European Congress of Dermato-Oncology (EADO) Congress and the American College of Mo</description>
</item>
<item>
<title>Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-to-release-first-quarter-2026-financial-results-and-host-webcast-on-wednesday-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-to-release-first-quarter-2026-financial-results-and-host-webcast-on-wednesday-may-6-2026</guid>
<pubDate>Wed, 15 Apr 2026 11:00:00 GMT</pubDate>
<description>Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the close of market on Wednesday, May 6, 2026.</description>
</item>
<item>
<title>Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-earns-2026-usa-today-top-workplaces-award-for-fifth-consecutive-year</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-earns-2026-usa-today-top-workplaces-award-for-fifth-consecutive-year</guid>
<pubDate>Fri, 10 Apr 2026 11:00:00 GMT</pubDate>
<description>Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received the 2026 USA TODAY Top Workplaces USA Award for the fifth consecutive year. The national award program by Energage and USA TODAY celebrates organizations with 150 or more employees that have built exceptional, people-first workplace cultures.</description>
</item>
<item>
<title>Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/prospective-multi-center-study-published-in-future-oncology-demonstrates-decisiondxr-melanomas-i31-slnb-result-outperforms-staging-criteria-in-identifying-patients-with-cutaneous-melanoma-below-the-5percent-nccn-threshold-for-forgoing-slnb</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/prospective-multi-center-study-published-in-future-oncology-demonstrates-decisiondxr-melanomas-i31-slnb-result-outperforms-staging-criteria-in-identifying-patients-with-cutaneous-melanoma-below-the-5percent-nccn-threshold-for-forgoing-slnb</guid>
<pubDate>Fri, 13 Mar 2026 15:02:00 GMT</pubDate>
<description>Among all patients studied, 2.6% nodal positivity and 97.8% three-year recurrence-free survival (RFS) was observed in those predicted to have less than 5% risk of a positive sentinel lymph node (SLN) by DecisionDx-Melanoma’s i31-SLNB Only 1.4% SLN positivity was observed in patients with T1b–T2a tumors predicted to have less than 5% risk The Company will host a webcast on Monday, March 23, at 4:30pm Eastern Time to discuss data from the publication FRIENDSWOOD, Texas, March 13, 2026 (GLOBE NEWSW</description>
</item>
<item>
<title>DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/decisiondxr-melanomas-i31-slnb-report-from-the-largest-prospective-multicenter-study-to-date-confirms-26percent-nodal-positivity-in-patients-predicted-to-have-less-than-5percent-risk</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/decisiondxr-melanomas-i31-slnb-report-from-the-largest-prospective-multicenter-study-to-date-confirms-26percent-nodal-positivity-in-patients-predicted-to-have-less-than-5percent-risk</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix. NCCN Cutaneous Melanoma Guidelines recommend</description>
</item>
<item>
<title>Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-to-present-data-at-sso-2026-on-decisiondxr-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb-63</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-to-present-data-at-sso-2026-on-decisiondxr-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb-63</guid>
<pubDate>Wed, 04 Mar 2026 21:30:00 GMT</pubDate>
<description>FRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity will be presented at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, being held March 5-7 in Phoenix. “The initial reports from the same prospective, multicenter study confirme</description>
</item>
<item>
<title>Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-announces-grand-opening-of-new-corporate-headquarters-in-friendswood-texas</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-announces-grand-opening-of-new-corporate-headquarters-in-friendswood-texas</guid>
<pubDate>Tue, 03 Mar 2026 21:30:00 GMT</pubDate>
<description>FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company’s new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and oth</description>
</item>
<item>
<title>Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-reports-fourth-quarter-and-full-year-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-reports-fourth-quarter-and-full-year-2025-results</guid>
<pubDate>Thu, 26 Feb 2026 21:05:00 GMT</pubDate>
<description>2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025.“We closed</description>
</item>
<item>
<title>Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/prospective-validation-study-in-jaad-demonstrates-castle-biosciences-advancead-txtm-test-identifies-patients-more-likely-to-achieve-faster-and-deeper-responses-with-jak-inhibitor-therapy-in-moderate-to-severe-atopic-dermatitis</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/prospective-validation-study-in-jaad-demonstrates-castle-biosciences-advancead-txtm-test-identifies-patients-more-likely-to-achieve-faster-and-deeper-responses-with-jak-inhibitor-therapy-in-moderate-to-severe-atopic-dermatitis</guid>
<pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
<description>Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time</description>
</item>
<item>
<title>Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-release-fourth-quarter-and-full-year-2025-financial-results-and</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-release-fourth-quarter-and-full-year-2025-financial-results-and</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide</description>
</item>
<item>
<title>Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-announces-preliminary-unaudited-fourth-quarter-and-full-year-2025</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-announces-preliminary-unaudited-fourth-quarter-and-full-year-2025</guid>
<pubDate>Sun, 11 Jan 2026 05:00:00 GMT</pubDate>
<description>2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers</description>
</item>
<item>
<title>Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12</guid>
<pubDate>Fri, 19 Dec 2025 05:00:00 GMT</pubDate>
<description>FRIENDSWOOD, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide</description>
</item>
<item>
<title>Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/landmark-study-shows-combination-castle-biosciences-decisiondxr-um-and-prame</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/landmark-study-shows-combination-castle-biosciences-decisiondxr-um-and-prame</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide</description>
</item>
<item>
<title>Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/systematic-review-and-meta-analysis-confirms-tissuecypherr-outperforms-traditional</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/systematic-review-and-meta-analysis-confirms-tissuecypherr-outperforms-traditional</guid>
<pubDate>Fri, 12 Dec 2025 05:00:00 GMT</pubDate>
<description>Across multiple published studies, the test consistently identifies high-risk patients whose progression rates exceed guideline-based actionable thresholds</description>
</item>
<item>
<title>Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/expert-melanoma-panel-recommends-castle-biosciences-decisiondxr-melanoma-best</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/expert-melanoma-panel-recommends-castle-biosciences-decisiondxr-melanoma-best</guid>
<pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
<description>Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanoma FRIENDSWOOD, Texas, Dec.</description>
</item>
<item>
<title>Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-earns-houston-chronicle-top-workplaces-award-fifth-consecutive</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-earns-houston-chronicle-top-workplaces-award-fifth-consecutive</guid>
<pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
<description>Castle also earns national recognition through three additional Top Workplaces Culture Excellence Awards — Employee Appreciation, Employee Well-Being and</description>
</item>
<item>
<title>New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/new-data-confirms-performance-decisiondxr-melanoma-identify-patients-less-five</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/new-data-confirms-performance-decisiondxr-melanoma-identify-patients-less-five</guid>
<pubDate>Fri, 14 Nov 2025 05:00:00 GMT</pubDate>
<description>Second study to be presented at the 2nd European Congress on Dermato-Oncology demonstrates DecisionDx-Melanoma can identify patients with a negative sentinel</description>
</item>
<item>
<title>Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-present-piper-sandler-37th-annual-healthcare-conference-2025-11-11</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-present-piper-sandler-37th-annual-healthcare-conference-2025-11-11</guid>
<pubDate>Tue, 11 Nov 2025 05:00:00 GMT</pubDate>
<description>FRIENDSWOOD, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide</description>
</item>
<item>
<title>Castle Biosciences Reports Third Quarter 2025 Results</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-reports-third-quarter-2025-results-2025-11-03</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-reports-third-quarter-2025-results-2025-11-03</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue</description>
</item>
<item>
<title>Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis</title>
<link>https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-launches-advancead-txtm-help-guide-systemic-treatment-decision</link>
<guid isPermaLink="true">https://6ix.com/company/castle-biosciences-inc/news/castle-biosciences-launches-advancead-txtm-help-guide-systemic-treatment-decision</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>Validation study data show AdvanceAD-Tx can identify patients with AD who have a ‘JAKi responder profile’ and a superior response to JAKi therapies compared</description>
</item>
</channel>
</rss>